
TSE:CGY
This summary was created by AI, based on 1 opinions in the last 12 months.
Calian Group Ltd (CGY-T) is receiving positive feedback from experts, highlighting its strong performance this quarter. The company has achieved a significant milestone by hitting a 52-week high, demonstrating its potential for growth and market momentum. Reviewers underscore the solid management and operational efficiency of Calian, which enhances its appeal as a long-term investment. Overall, the outlook appears optimistic, suggesting that investors should consider maintaining their position in this well-run company. The positive sentiment indicates a strong belief in Calian's future performance based on recent achievements and management stability.
He used to own it a long time ago. It stalled out and he sold. It is finally getting traction again. They are trying to diversify the business. If they lose a big contract it could really impact the results. The dividend is safe. He would like to buy it much more cheaply but he would not buy at these levels.
It does 145 pharmacies by Loblaw’s (L-T) and medical services for the Canadian Defence Department, as well as a satellite business out of Saskatoon. One of the most consistently profitable small-cap companies for the last 5 years. 4% dividend yield. (Analysts’ price target is $31.00.)